Patents by Inventor Makoto Koizumi

Makoto Koizumi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11230709
    Abstract: The present invention aims at establishing a molecular therapy for Alport syndrome. The present invention provides an oligonucleotide of 15-30 bp comprising a nucleotide sequence complementary to the cDNA of COL4A5 gene, wherein the oligonucleotide is capable of inducing skipping of an exon which has a truncating mutation found in COL4A5 gene in Alport syndrome patients and whose nucleotide number is a multiple of 3, a pharmaceutically acceptable salt thereof, or a solvate thereof. Also provided is a pharmaceutical drug comprising the above oligonucleotide, a pharmaceutically acceptable salt thereof, or a solvate thereof (therapeutic drug for Alport syndrome).
    Type: Grant
    Filed: December 25, 2017
    Date of Patent: January 25, 2022
    Assignees: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, DAIICHI SANKYO COMPANY LIMITED
    Inventors: Kazumoto Iijima, Kandai Nozu, Akemi Shono, Makoto Koizumi, Yoshiyuki Onishi, Kiyosumi Takaishi, Tomomi Adachi
  • Publication number: 20210281732
    Abstract: The present technology relates to a signal processing device, an imaging device, and a signal processing method which are capable of recognizing a blinking target object reliably and recognizing an obstacle accurately, in a situation in which a luminance difference is very large. Signals of a plurality of images captured at different exposure times are added using different saturation signal amounts, and signals of a plurality of images obtained as a result of the addition are synthesized, and thus it is possible to recognize a blinking target object reliably and recognize an obstacle accurately, in a situation in which a luminance difference is very large. The present technology can be applied to, for example, a camera unit or the like that captures an image.
    Type: Application
    Filed: September 8, 2017
    Publication date: September 9, 2021
    Inventors: MAKOTO KOIZUMI, MASAKATSU FUJIMOTO, IKKO OKAMOTO, DAIKI YAMAZAKI
  • Publication number: 20210207136
    Abstract: The present invention establishes a method for treating cardiac dysfunction. An oligonucleotide of 15-30 bp comprising a nucleotide sequence complementary to a part of the intron 55 region of a dystrophin gene, which comprises the sequence of 5?-TGTCTTCCT-3? or 5?-CAGCTTGAACCGGGC-3? (SEQ ID NO: 64) (wherein “T” may be “U” in either sequence), a pharmacologically acceptable salt thereof, or a solvate thereof. A prophylactic and/or a therapeutic for cardiac dysfunction, comprising the above-described oligonucleotide, a pharmacologically acceptable salt thereof, or a solvate thereof. A suppressor of Dp116 expression, comprising the above-described oligonucleotide, a pharmacologically acceptable salt thereof, or a solvate thereof.
    Type: Application
    Filed: June 12, 2019
    Publication date: July 8, 2021
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, KOBE GAKUIN EDUCATIONAL FOUNDATION
    Inventors: Masafumi MATSUO, Makoto KOIZUMI, Yoshiyuki ONISHI, Takao SHOJI
  • Patent number: 11015202
    Abstract: The present invention provides an oligodeoxynucleotide containing humanized K type CpG oligodeoxynucleotide and poly deoxyadenylate, wherein the poly deoxyadenylate is placed on the 3?-side of the humanized K type CpG oligodeoxynucleotide. In addition, the present invention provides a complex containing the aforementioned oligodeoxynucleotide and ?-1,3-glucan.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: May 25, 2021
    Assignees: NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Ken Ishii, Kouji Kobiyama, Taiki Aoshi, Fumihiko Takeshita, Yuji Kasuya, Takako Niwa, Makoto Koizumi
  • Publication number: 20210136301
    Abstract: The imaging apparatus includes a remaining battery level detection unit, a solid-state imaging element, and a control unit. In the imaging apparatus, the remaining battery level detection unit detects a remaining battery level of the battery. Furthermore, in the imaging apparatus, the solid-state imaging element captures image data. Moreover, in the imaging apparatus, the control unit controls the solid-state imaging element to capture image data so that the lower the remaining battery level measured by a remaining battery level measurement unit, the smaller the data amount of the image data to be captured in synchronization with a predetermined synchronization signal.
    Type: Application
    Filed: May 11, 2018
    Publication date: May 6, 2021
    Inventor: Makoto Koizumi
  • Patent number: 10999520
    Abstract: The present technology relates to an image capture device, a method of image capture, a signal processing device, a method of signal processing, and a program capable of capturing reliably a blinking image capture target. A predetermined image capture timing of an image capture unit is controlled so that image capture is performed N times during an exposure time in which at least a part of a turn-on period in which an image capture target is on overlaps with an exposure time of image capture of at least one time at a timing of dividing a blinking cycle in which the image capture target to be captured by the image capture unit configured to perform image capture at the image capture timing blinks into N equal parts where N represents more than one. The present technology is applicable to, in one example, a camera unit or the like used to capture an image.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: May 4, 2021
    Assignee: Sony Corporation
    Inventors: Makoto Koizumi, Hiroyuki Tanaka, Jun Ono, Daisuke Kawamata, Masakatsu Fujimoto
  • Publication number: 20210087560
    Abstract: An object of the present invention is to provide a vector capable of oligodendrocyte-specifically suppressing expression of the PLP1 gene for treating PMD caused by abnormality of the PLP1 gene, and a promoter and miRNA therefor, and a pharmaceutical composition comprising the vector. The oligodendrocyte-specific promoter of the present invention comprises a nucleic acid having a sequence identity of at least 90% to a nucleotide sequence set forth in SEQ ID NO: 1. The miRNA of the present invention specific to the PLP1 gene comprises a pair of nucleotide sequences consisting of a specific antisense sequence and sense sequence.
    Type: Application
    Filed: February 6, 2019
    Publication date: March 25, 2021
    Applicants: NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, NIPPON MEDICAL SCHOOL FOUNDATION, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Ken Inoue, Heng Li, Takashi Okada, Yu Ohki, Makoto Koizumi
  • Publication number: 20210006777
    Abstract: To enable detection of occurrence of abnormality in a more preferable manner when the abnormality occurs in signal processing applied to pixel signals.
    Type: Application
    Filed: December 10, 2018
    Publication date: January 7, 2021
    Inventors: MAKOTO KOIZUMI, MASAKI MUROZUKA, MASAKATSU FUJIMOTO
  • Publication number: 20200407394
    Abstract: The present invention establishes a molecular therapy for glycogen storage disease type Ia. The present invention provides an oligonucleotide of 15-30 bases comprising a nucleotide sequence complementary to the cDNA of G6PC gene with c.648G>T mutation, wherein the oligonucleotide comprises a sequence complementary to a region comprising any site between the 82nd to the 92nd nucleotide from the 5? end of exon 5 of the G6PC gene with c.648G>T mutation, a pharmacologically acceptable salt or solvate thereof. Also provided is a pharmaceutical drug comprising the oligonucleotide, a pharmacologically acceptable salt or solvate thereof (e.g., therapeutic drug for glycogen storage disease type Ia).
    Type: Application
    Filed: March 5, 2019
    Publication date: December 31, 2020
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, KOBE GAKUIN EDUCATIONAL FOUNDATION
    Inventors: Makoto KOIZUMI, Yoshiyuki ONISHI, Takeshi MASUDA, Mitsuhiro IWAMOTO, Yukiko SEKIGUCHI, Kentaro ITO, Shinnosuke TSUJI, Masafumi MATSUO
  • Patent number: 10805548
    Abstract: The present technology relates to a signal processing apparatus, an imaging apparatus, and a signal processing method capable of reliably imaging a blinking imaging target in a scene having a very large difference in brightness. By detecting a difference between a plurality of images captured with different exposure times, calculating a combination coefficient indicating a combination ratio between the plurality of images on the basis of the difference, and combining the plurality of images on the basis of the combination coefficient, it is possible to reliably image a blinking imaging target in a scene having a very large difference in brightness. The present technology can be applied to, for example, a camera unit that captures an image.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: October 13, 2020
    Assignee: Sony Semiconductor Solutions Corporation
    Inventors: Makoto Koizumi, Masakatsu Fujimoto, Ikko Okamoto, Daiki Yamazaki, Yasushi Shibata
  • Patent number: 10731159
    Abstract: The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: August 4, 2020
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Makoto Koizumi, Yoshiyuki Onishi, Takako Niwa, Masakazu Tamura, Yuji Kasuya
  • Publication number: 20200172903
    Abstract: The objective of the present invention is to provide nucleic acid therapeutics which exhibits more excellent effect and which shows a substantivity for a prolonged period to suppress an expression of ?-synuclein. The oligonucleotide or a pharmacologically acceptable salt thereof according to the present invention is characterized in comprising at least one 2?-O,4?-C-ethylene nucleoside, wherein the oligonucleotide can hybridize with ?-synuclein gene, has an activity to suppress an expression of the ?-synuclein gene, and is complementary to the ?-synuclein gene, 5? end of the oligonucleotide is a nucleotide complementary to the specific nucleotide, the oligonucleotide is complementary to at least a part of SEQ ID NO: 1, and the oligonucleotide has a length of 13 or more and 15 or less nucleotides.
    Type: Application
    Filed: July 3, 2018
    Publication date: June 4, 2020
    Inventors: Masayuki NAKAMORI, Hideki MOCHIZUKI, Satoshi OBIKA, Makoto KOIZUMI, Akifumi NAKAMURA, Kiyosumi TAKAISHI, Yumiko ASAHI
  • Publication number: 20200080086
    Abstract: The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.
    Type: Application
    Filed: November 22, 2019
    Publication date: March 12, 2020
    Inventors: Makoto KOIZUMI, Yoshiyuki ONISHI, Takako NIWA, Masakazu TAMURA, Yuji KASUYA
  • Publication number: 20200080080
    Abstract: The present invention aims at establishing a molecular therapy for Alport syndrome. The present invention provides an oligonucleotide of 15-30 bp comprising a nucleotide sequence complementary to the cDNA of COL4A5 gene, wherein the oligonucleotide is capable of inducing skipping of an exon which has a truncating mutation found in COL4A5 gene in Alport syndrome patients and whose nucleotide number is a multiple of 3, a pharmaceutically acceptable salt thereof, or a solvate thereof. Also provided is a pharmaceutical drug comprising the above oligonucleotide, a pharmaceutically acceptable salt thereof, or a solvate thereof (therapeutic drug for Alport syndrome).
    Type: Application
    Filed: December 25, 2017
    Publication date: March 12, 2020
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY
    Inventors: Kazumoto IIJIMA, Kandai NOZU, Akemi SHONO, Makoto KOIZUMI, Yoshiyuki ONISHI, Kiyosumi TAKAISHI, Tomomi ADACHI
  • Publication number: 20200029005
    Abstract: The present technology relates to an image capture device, a method of image capture, a signal processing device, a method of signal processing, and a program capable of capturing reliably a blinking image capture target. A predetermined image capture timing of an image capture unit is controlled so that image capture is performed N times during an exposure time in which at least a part of a turn-on period in which an image capture target is on overlaps with an exposure time of image capture of at least one time at a timing of dividing a blinking cycle in which the image capture target to be captured by the image capture unit configured to perform image capture at the image capture timing blinks into N equal parts where N represents more than one. The present technology is applicable to, in one example, a camera unit or the like used to capture an image.
    Type: Application
    Filed: July 29, 2019
    Publication date: January 23, 2020
    Applicant: Sony Corporation
    Inventors: Makoto Koizumi, Hiroyuki Tanaka, Jun Ono, Daisuke Kawamata, Masakatsu Fujimoto
  • Patent number: 10533176
    Abstract: The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: January 14, 2020
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Makoto Koizumi, Yoshiyuki Onishi, Takako Niwa, Masakazu Tamura, Yuji Kasuya
  • Publication number: 20190335079
    Abstract: The present technology relates to a signal processing apparatus, an imaging apparatus, and a signal processing method capable of reliably imaging a blinking imaging target in a scene having a very large difference in brightness. By detecting a difference between a plurality of images captured with different exposure times, calculating a combination coefficient indicating a combination ratio between the plurality of images on the basis of the difference, and combining the plurality of images on the basis of the combination coefficient, it is possible to reliably image a blinking imaging target in a scene having a very large difference in brightness. The present technology can be applied to, for example, a camera unit that captures an image.
    Type: Application
    Filed: June 30, 2017
    Publication date: October 31, 2019
    Applicant: Sony Semiconductor Solutions Corporation
    Inventors: Makoto Koizumi, Masakatsu Fujimoto, Ikko Okamoto, Daiki Yamazaki, Yasushi Shibata
  • Patent number: 10412309
    Abstract: The present technology relates to an image capture device, a method of image capture, a signal processing device, a method of signal processing, and a program capable of capturing reliably a blinking image capture target. A predetermined image capture timing of an image capture unit is controlled so that image capture is performed N times during an exposure time in which at least a part of a turn-on period in which an image capture target is on overlaps with an exposure time of image capture of at least one time at a timing of dividing a blinking cycle in which the image capture target to be captured by the image capture unit configured to perform image capture at the image capture timing blinks into N equal parts where N represents more than one. The present technology is applicable to, in one example, a camera unit or the like used to capture an image.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: September 10, 2019
    Assignee: Sony Corporation
    Inventors: Makoto Koizumi, Hiroyuki Tanaka, Jun Ono, Daisuke Kawamata, Masakatsu Fujimoto
  • Publication number: 20190112606
    Abstract: The present invention provides an oligodeoxynucleotide containing humanized K type CpG oligodeoxynucleotide and poly deoxyadenylate, wherein the poly deoxyadenylate is placed on the 3?-side of the humanized K type CpG oligodeoxynucleotide. In addition, the present invention provides a complex containing the aforementioned oligodeoxynucleotide and ?-1,3-glucan.
    Type: Application
    Filed: December 20, 2018
    Publication date: April 18, 2019
    Applicants: NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Ken ISHII, Kouji KOBIYAMA, Taiki AOSHI, Fumihiko TAKESHITA, Yuji KASUYA, Takako NIWA, Makoto KOIZUMI
  • Patent number: 10202606
    Abstract: The present invention provides an oligodeoxynucleotide containing humanized K type CpG oligodeoxynucleotide and poly deoxyadenylate, wherein the poly deoxyadenylate is placed on the 3?-side of the humanized K type CpG oligodeoxynucleotide. In addition, the present invention provides a complex containing the aforementioned oligodeoxynucleotide and ?-1,3-glucan.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: February 12, 2019
    Assignees: NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Ken Ishii, Kouji Kobiyama, Taiki Aoshi, Fumihiko Takeshita, Yuji Kasuya, Takako Niwa, Makoto Koizumi